Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer - ScienceDirect
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies
Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases | Scientific Reports
PDF) Normal CA 19-9 levels in Hashimoto's thyroiditis
Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma | Scientific Reports
Clinical analysis of four serum tumor markers in 458 patients with ova | CMAR
PDF) CA 19-9 as a serum marker in urothelial carcinoma
CA 19-9: Reference Range, Interpretation, Collection and Panels
CA 19-9: handle with care
The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. | Semantic Scholar
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial - The Lancet Oncology
Tumor Marker:- Part 7 - CA 125 and CA 19-9 - Labpedia.net
Table 1 from Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. | Semantic Scholar
![PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a96fc01f495907ea18214fdc7db7ffd9b210d72c/2-TableI-1.png "PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar")
PDF] Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors | Semantic Scholar
Carbohydrate antigen 19-9 — tumor marker: Past, present, and future
PDF) CA 19-9 as a serum marker in urothelial carcinoma
Summary of CA 72-4, TAG-72, and CEA serum levels in patients with... | Download Table
CA19-9 - Wikipedia
Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer - HPB
Clinical utility of tumor marker cutoff ratio and a combination scoring system of preoperative carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4 levels in gastric cancer. - Abstract - Europe PMC
